Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2014 | 12-2013 | 12-2006 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 21,221 | 11,801 | 0 | N/A |
| TOTAL | $21,622 | $12,161 | $0 | $N/A |
| Non-Current Assets | ||||
| PPE Net | 35 | 39 | 0 | N/A |
| Other Non-Current Assets | 0 | 117 | 0 | 0 |
| TOTAL | $35 | $156 | $N/A | $N/A |
| Total Assets | $21,658 | $12,317 | $0 | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | 3,208 | 1,906 | 0 | N/A |
| Accounts payable and accrued liabilities | 678 | 931 | 0 | 0 |
| Accrued Expenses | 1,886 | 975 | 0 | N/A |
| Other current liabilities | 78 | 1,182 | 0 | N/A |
| TOTAL | $5,850 | $4,994 | $0 | $N/A |
| Non-Current Liabilities | ||||
| Long Term Debt | 2,354 | 5,308 | 0 | N/A |
| Other Non-Current Liabilities | 371 | 0 | 0 | 0 |
| TOTAL | $2,724 | $5,308 | $N/A | $N/A |
| Total Liabilities | $8,574 | $10,302 | $0 | $N/A |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 3 | N/A | N/A | N/A |
| Common Shares | 9 | 1 | 0 | N/A |
| Retained earnings | -53,564 | -43,073 | 0 | N/A |
| Other shareholders' equity | 0 | 28,346 | 0 | 0 |
| TOTAL | $13,084 | $2,015 | $0 | $N/A |
| Total Liabilities And Equity | $21,658 | $12,317 | $0 | $0 |